Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Consensus Target Price from Analysts

Mersana Therapeutics, Inc. (NASDAQ:MRSN) has been given a consensus rating of “Moderate Buy” by the eight brokerages that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $6.00.

Separately, Citigroup assumed coverage on shares of Mersana Therapeutics in a research report on Friday, November 15th. They set a “buy” rating and a $5.00 target price on the stock.

Institutional Trading of Mersana Therapeutics

Large investors have recently made changes to their positions in the company. Los Angeles Capital Management LLC raised its holdings in Mersana Therapeutics by 8.1% during the 3rd quarter. Los Angeles Capital Management LLC now owns 189,660 shares of the company’s stock worth $358,000 after buying an additional 14,240 shares during the period. US Bancorp DE bought a new stake in Mersana Therapeutics in the 3rd quarter valued at $31,000. Dynamic Technology Lab Private Ltd bought a new stake in Mersana Therapeutics in the 3rd quarter valued at $34,000. Renaissance Technologies LLC boosted its stake in Mersana Therapeutics by 1.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,448,219 shares of the company’s stock worth $2,911,000 after purchasing an additional 20,400 shares during the period. Finally, Intech Investment Management LLC bought a new position in Mersana Therapeutics during the 3rd quarter worth about $52,000. Institutional investors own 93.92% of the company’s stock.

Mersana Therapeutics Price Performance

Shares of MRSN stock opened at $1.42 on Friday. The firm has a market cap of $175.42 million, a P/E ratio of -2.33 and a beta of 1.40. The firm has a fifty day moving average of $2.10 and a two-hundred day moving average of $1.93. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. Mersana Therapeutics has a 1-year low of $1.22 and a 1-year high of $6.28.

Mersana Therapeutics (NASDAQ:MRSN) last released its earnings results on Wednesday, November 13th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.08. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The company had revenue of $12.60 million for the quarter, compared to analyst estimates of $7.53 million. During the same quarter last year, the firm earned ($0.35) EPS. The firm’s quarterly revenue was up 63.6% compared to the same quarter last year. As a group, research analysts anticipate that Mersana Therapeutics will post -0.61 earnings per share for the current fiscal year.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.